<DOC>
	<DOC>NCT01611883</DOC>
	<brief_summary>This study will examine the effect of ezetimibe on glucose metabolism in participants with Type 2 diabetes and hypercholesterolemia.The primary hypothesis is that change in glycated hemoglobin (HbA1c) from baseline in the ezetimibe treatment group will be non-inferior to the placebo control group.</brief_summary>
	<brief_title>A Study of the Effect of Ezetimibe on Glucose Metabolism in Type 2 Diabetics With Hypercholesterolemia (P06541)</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<criteria>Have hypercholesterolemia (high cholesterol) and have been diagnosed with type 2 diabetes that is being treated with oral antidiabetic drugs or insulin or both. No change in the medication (drugs, dose and administration) for the treatment of diabetes within previous 12 weeks with exception of small changes in insulin dosing No change in diet and exercise therapy within previous 4 weeks Coexisting disease (hemoglobinopathy, hemolytic anemia, etc.) that may affect HbA1c measurement Homozygous or heterozygous familial hypercholesterolemia Previously received ezetimibe Hypercholesterolemia associated with: hypothyroidism, obstructive gall bladder or biliary disease, chronic renal failure or pancreatitis Hyperlipidemia caused by medication</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>